Corrigendum to "Pazopanib in the treatment of advanced renal cell carcinoma" by David Cella and Jennifer L. Beaumont, Therapeutic Advances in Urology, 2016, Vol. 8(1) 61-69. DOI: 10.1177/1756287215614236

Page 65, column 2, lines 7–13 The following text did not appear correctly in the article: "OS for the favorable/intermediate prognostic groups (according to MSKCC criteria) was not reached (NR)/12 months while PFS was 25/17 months. For the favorable/intermediate prognostic groups as assessed according to Heng criteria, OS was NR/12 months while PFS was NR/25 months." The correct text reads as follows: "PFS for the favorable/intermediate prognostic groups (according to MSKCC criteria) was not reached (NR)/12 months while OS was 25/17 months. For the favorable/intermediate prognostic groups as assessed according to Heng criteria, PFS was NR/12 months while OS was NR/25 months." The authors apologize for this error in their submission.
Source: Therapeutic Advances in Urology - Category: Urology & Nephrology Tags: Corrigendum Source Type: research